Not provided
Not provided
Not provided
Not provided
Not provided
Insufficient patient eligible for recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The use of dobutamine in postoperative hemodynamic treatment is widespread despite seemingly intact contraction of the heart. This study aims to elucidate the efficacy of low-dose dobutamine infusion in patients in the postoperative phase replacement of the aortic valve.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dobutamine | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dobutamine | Drug | 90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac output | Change in cardiac output (l/min) from initiation of study drug or placebo until 90 minutes of infusion. | From 0 to 90 minutes after drug initiation |
| Measure | Description | Time Frame |
|---|---|---|
| Mean pulmonary artery pressure | Changes in pulmonary artery pressure (mmHg) from start of study drug or placebo infusion until 90 minutes after the start. | From 0 to 90 minutes after drug initiation. |
| Echocardiography |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Erik Sloth, Professor | Department of Anaesthesia & Intensive Care, Århus Univerisity Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anaesthesia & Intensive Care, Århus University Hospital | Aarhus | 8200 | Denmark |
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D004280 | Dobutamine |
| ID | Term |
|---|---|
| D002395 | Catecholamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D010627 | Phenethylamines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Echocardiographic measures of systolic and diastolic heart function.
| From 0 minutes to 90 minutes after drug initiation |
| Changes in mixed venous saturation | Changes in mixed venous saturation (in per cent) from baseline until the end of dobutrex or placebo infusion. | From 0 minutes to 90 minutes after drug initiation |
| norepinephrine requirement | The amount of norepinephrinem(mg) required to maintain adequate systemic blood pressure during the infusion period of dobutrex and placebo | From 0 minutes to 90 minutes after drug initiation |
| Central venous pressure | Changes in CVP from baseline until 90 minutes of study drug or placebo infusion. | From 0 minutes to 90 minutes after drug initiation |
| D005021 |
| Ethylamines |
| D002396 | Catechols |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |